VQD-002 triciribine phosphate monohydrate: Phase I/II start

In mid-2008, NCI's Center for Cancer Research will start a Phase I/II trial of VQD-002 in combination with Tarceva erlotinib in 30-50 patients. Genentech Inc. (NYSE:DNA, South San Francisco, Calif.)...